It has now been more than a decade since the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule became effective, following years of conflicts that pitted multiple interests against one another: individual privacy rights, access to personal health information in public health and research endeavors, the economic interests of the health-care sector, and an expanding government role in health care. These influences combined to produce a convoluted and leaky regulatory system that, paradoxically perhaps, has been criticized since its inception as both burdensome to providers and inadequate to assure health information privacy and security for individual patients. 1 Four years after the enactment of major HIPAA reforms in the Health Information Technology for Economic and Clinical Health (HITECH) Act, 2 the U.S. Department of Health and Human Services (HHS) has issued an Omnibus Rule that reflects movement to strengthen individual rights while continuing to facilitate the other competing interests, including those of public health, in greater access to health information.
This installment of Law and the Public's Health explores the evolution of HIPAA's privacy protections. After a brief description of the history and structure of HIPAA, we highlight key provisions of the recently released final rules and explore their implications for public health policy and practice.
bacKground
Ensuring the privacy and confidentiality of health information has always been a critical aspect of health care, but until the enactment of HIPAA, no comprehensive piece of federal legislation protected health information privacy. Pursuant to the law, Congress gave itself two years to enact federal privacy protections, but in the end tasked HHS with the job of promulgating privacy and security regulations. 3 Following years of negotiations, federal regulations implementing HIPAA's privacy provisions were issued in 2000, 4 revised in 2002, 5 and became effective for most entities in 2003. 6 The HIPAA Privacy Rule regulates the use and disclosure of protected health information (PHI) by "covered entities," defined as health plans, health care clearinghouses, and health care providers who transmit health information in electronic form. PHI is "individually identifiable health information" that is held or transmitted by a covered entity in any form, paper or electronic. 7 Under the Privacy Rule, covered entities may not use or disclose PHI except as permitted or required. Only two types of disclosures are required: when a patient requests his/her own PHI and when the Secretary of HHS requests PHI for audit or other enforcement purposes. 8 All other disclosures, including those that may be required by other federal or state laws (e.g., public health reporting statutes), are considered "permitted," or allowed by the Privacy Rule. 9 For example, covered entities are permitted to access, use, and disclose PHI for the purposes of treatment, payment, and health care operations. 10 Written "authorizations" by patients are required for uses and disclosures of PHI that are not otherwise permitted or required; as a result, many disclosures, including those related to treatment, payment, and health care operations, require no authorization. 11
Public health operations have been largely exempted from HIPAA's restrictions. That is, HIPAA permits, but does not require, covered entities to disclose PHI without authorization to public health authorities for activities including, among others, reporting; surveillance, investigations, and interventions; and notifying people at risk of communicable disease. 12 The Privacy Rule, therefore, allows public health authorities to engage in the full range of activities authorized by state law, assuming successful collection of necessary data from covered entities (as either PHI or in less identifiable forms 13,14 allowed by the regulations). 15 Although establishment of HIPAA's privacy provisions was a watershed in federal health information privacy law, gaps in the Privacy Rule's protections existed. These gaps have been amplified with the increased use of health information technology, which promises not only the possibility of comprehensive health records that can move with individuals over a lifetime, but also more efficient gathering of data that could lead to improved population health. For example, because HIPAA applies only to covered entities as defined in the statute, many of the new entities that store and/or manage PHI electronically have not been covered by the Privacy Rule. Other perceived deficiencies in the Privacy Rule have included its lack of a breach notification standard, concerns about the de-identification and limited data set provisions, objections to the use of consumers' PHI for marketing purposes, and complaints about oversight and enforcement activities. 3 HITECH addressed many of these perceived deficiencies by (1) strengthening individual control over, and access to, data; (2) broadening the definition of who is considered a business associate of a covered entity (and thereby expanding the universe of entities covered by HIPAA) and increasing business associate duties; (3) creating a federal breach notification standard; (4) placing new restrictions on the marketing and sale of PHI; (5) requiring guidance on the use of de-identified data and limited data sets; and (6) adding new enforcement provisions and increasing penalties for violations. At the same time, HITECH retained HIPAA's basic legal structure to preserve the ability of public health agencies to establish standards for the reporting of important public health data and to use those data to monitor population health, incidence of disease, and effectiveness of treatment and care. 15 HHS released the Omnibus Rule implementing HITECH's provisions on January 17, 2013. 16 The Rule combines and replaces four previously issued proposed and interim final rules and became effective on March 26, 2013. [17] [18] [19] [20] tHe omnibuS rule
Patient access and control
The Omnibus Rule expands an individual's right to receive an electronic copy of his/her PHI. 21 In addition, the Omnibus Rule implements HITECH's requirement that providers follow patient requests that their PHI not be disclosed to a health plan for payment or health care operations purposes if the disclosure is not required by law and relates solely to items or services for which the patient paid out of pocket in full. 22
Accountability
The Omnibus Rule expands the definition of a "business associate" to include all entities that create, receive, maintain, or transmit PHI on behalf of a covered entity, 7 making clear that companies that store PHI on behalf of health care providers and health plans are business associates. 23 This change extends HIPAA's requirements to a broader group of businesses that handle and have the capability to access identifiable health data, including health information organizations and patient safety organizations.
Further, HITECH made clear that business associates are now directly subject to most provisions of the HIPAA Security Rule as well as certain provisions of the Privacy Rule. 15 The Omnibus Rule clarifies that the definition of a business associate also includes relevant subcontractors, ensuring that a covered entity's or business associate's security requirements encompass outsourced operations. 7
Marketing restrictions
The Privacy Rule generally prohibited the use or disclosure of PHI for marketing purposes without an individual's authorization, but traditionally allowed a number of exceptions. The Omnibus Rule tightened this approach, so that PHI may no longer be used in most marketing activities without patient authorization if the covered entity is compensated for making the communication by a third party (e.g., a pharmaceutical company) that is promoting its own product. In-kind benefits received by the covered entity (e.g., brochures, even if supplied by the third party) are not considered prohibited remuneration. HITECH also included a provision permitting third-party-sponsored communications to patients regarding drugs or biologics that they already have been prescribed (or generic substitutes). The Omnibus Rule permits payments for such communications (e.g., by a pharmaceutical company to a pharmacy for refill reminders) as long as the payment reasonably relates to the cost of the communication. 24
Reasonable disclosures
Of particular note to public health practitioners, the Omnibus Rule makes the release of student immunization information to schools less cumbersome by allowing covered entities to disclose the immunization records of students or prospective students to a school if state law requires the school to have proof of immunization and the covered entity obtains and documents the agreement of the parent or guardian. 12
Genetic information
As required by the Genetic Information Nondiscrimination Act of 2008, the Omnibus Rule incorporates genetic information into the definition of PHI, thereby explicitly applying HIPAA's privacy protections to individual genetic information. 7
Sale of PHI
In accordance with HITECH's requirements, the Omnibus Rule generally prohibits the sale of PHI, defined as remuneration (financial or otherwise) in exchange for PHI, without individual authorization. Certain exceptions are allowed, including the sale of PHI for certain public health purposes (without restriction as to price) and sales for use in research if the remuneration is limited to a reasonable cost-based fee to cover the cost to prepare and transmit the PHI. 9
Research
The Omnibus Rule has simplified HIPAA's consent requirements for research participation so that some studies involving PHI that have been required to use multiple consent forms will now be permitted to use a single form, which may prove less confusing to participants. 25 In addition, the Omnibus Rule offers a means for researchers to obtain "prospective consent" for future studies, a change from previous HHS interpretation of the Privacy Rule as requiring study-specific research authorizations. 26 This change facilitates the use of authorizations that are broad enough to encompass a range of future research projects; for example, the need for analysis of a biomarker, a genetic association, or a behavioral link might not be apparent when a study is begun, but could be critical at a future date. The Omnibus Rule now allows the use of prospective consent in such cases, as long as an individual receives an adequate description of the scope of potential future research so that individuals can reasonably anticipate how their PHI might be used. 27
Breach notice HITECH required that covered entities notify individuals whose unsecured PHI has been disclosed as a result of a privacy or security breach. 15 The Omnibus Rule replaces a controversial "risk of harm" breach standard from an earlier version of the rule 23 with an objective requirement that covered entities treat improper disclosures of PHI presumptively as breaches unless certain statutory conditions exist (e.g., demonstration that the data were encrypted) or the covered entity can demonstrate a low probability that PHI has been compromised. The latter requires a four-part risk assessment that includes consideration of whether the data were actually acquired or viewed by an unauthorized person and the extent of mitigation accomplished. 28
Penalties
The Omnibus Rule clarifies that assessment of violations includes consideration of the number of individuals affected, the length of noncompliance, and the severity of culpability. 29, 30 Penalties may reach a cap of $1.5 million per identical violation type per year. 31
Implementation
In general, covered entities and their business associates had until September 23, 2013, to comply with the provisions of the Omnibus Rule. Under certain circumstances, covered entities are permitted up to one additional year to amend existing business associate contracts. 32 imPlicationS For Public HealtH PolicY and Practice HITECH addressed some of the gaps in the Privacy Rule's protections and, therefore, may help build public trust in the new environment of increased digitization of health data. 23 As the product of two statutes and a prolonged rulemaking process, the Omnibus Rule has produced a changed landscape for health information.
The Omnibus Rule has significantly tightened HIPAA's requirements for business associates, making it clear that they (and their subcontractors) must comply with its restrictions and can be held directly accountable for failure to do so. Moreover, the universe of entities covered by the law has widened and now encompasses, for example, health information exchange networks and personal health records (PHRs) that are offered through a covered entity's electronic health record. 23 The Omnibus Rule also strengthens individuals' control over their own data, including the right to restrict disclosure of PHI for purposes of carrying out payment or health care operations.
Nevertheless, HIPAA continues to reflect the inherent tension between the interests of public health and the rights of individuals. While core public health duties have long required access to data for surveillance and response, demands for access to more extensive health information have grown, as some argue that serious public health concerns justify increased intrusion into personal health information. The Omnibus Rule retains HIPAA's basic structure in this regard and ensures the availability of PHI for public health purposes; indeed, the Omnibus Rule not only exempts public health purposes from its general proscription against the sale of PHI, 9 but covered entities are not restricted to selling PHI for such purposes at cost. 33 The Omnibus Rule also continues to support the use of both limited data sets and de-identified data without individual authorization, 15 although neither type of data may ultimately prove reliable in maintaining confidentiality. HHS itself has noted a level of risk of re-identification of such data, 34 yet a critical aspect of current public health analyses is the integration of such data sets.
Ultimately, the foundation for the collection of public health data is public trust, which requires the formulation of policy that carefully considers both individual rights and collective goods. As the Institute of Medicine has reported that 58% of Americans think laws and practices do not adequately protect their health information 35 and only about one in 10 Americans supports sharing data with researchers without consent, 36 critical questions remain regarding whether the Omnibus Rule has adequately addressed such concerns.
looKing aHead HHS has not yet completed its work on HITECH. Rulemaking to ensure greater transparency regarding disclosure of identifiable health data from electronic records is not complete and additional guidance is needed regarding the status of PHRs that are not covered by HIPAA and HIPAA's requirements to use or disclose only the minimum amount of health information necessary to achieve a covered entity's purpose. 23 As technology rapidly advances and health information is gathered and stored in many environments, a more critical gap in HIPAA's protection of identifiable health data persists: it remains a context-centric approach to health information privacy. Data are protected largely based on when and by whom it was acquired. Most Americans are likely to view such "context" as a distinction without a difference-their health information is personal, valuable, and potentially vul-nerable to misuse. It is likely that the tug of war over individual health data has not yet ended.
